fda compounding semaglutide enforcement november 2025 Compounded "semaglutide" is not FDA-approved FDA Update: Current Guidelines for

The compounds work differently enough that direct dose translation is not valid

Prevention candidates: Given the observational data suggesting reduced autoimmune disease risk in GLP-1 users, some practitioners are considering microdosing for patients with strong family histories or early biomarker evidence of autoimmune activation before clinical disease manifests

doi: 10.2337/dc13-2112 64 YapanisMJamesSCraigMEONealDEkinciEI

Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database

Being an investigational drug, retatrutide is not yet available